Accessibility Plan
Accessibility Plan
Search
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Vancouver General Hospital pilots new plant-rich menu items for health of patients and planet
Accessibility Plan - EN
Accessibility Statement
Accessability Statement
More Green
More Green
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
New initiative helps over 16,000 healthcare providers gain critical knowledge about palliative care during COVID-19
Accessible Customer Service Policy
Accessible Customer Service Policy
Boehringer Ingelheim increases commitments to sustainable development
Boehringer Ingelheim increases commitments to sustainable development
Our Responsibility
Our Responsibility
Skin Diseases
Skin Diseases
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
Digital Clinical Support Tool Aims to Individualize Guidelines-Based Diabetes Care
BURLINGTON, ON – October 11, 2023 – Boehringer Ingelheim (Canada) Ltd. and BI X, the digital lab of Boehringer Ingelheim, have collaborated to introduce a new digital clinical support tool for Canadian healthcare professionals managing the care
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Improving health outcomes for patients living with interstitial lung disease and addressing the gaps in care is the aim of a new collaboration
Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba
Research Manitoba and Boehringer Ingelheim Canada Partnership to Invest in Diabetes Care in Indigenous Populations in Manitoba
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases
PIPEDA Terms of Use Consent - Contact us form - english
PIPEDA Terms of Use Consent - Contact us form - english
Legal Notices
Legal Notices
Boehringer Ingelheim Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) complete negotiations for OFEV® (nintedanib) for PF-ILD
OFEV® is the first and only treatment available in Canada for progressive fibrosing interstitial lung diseases (PF-ILD), which affects patients across a wide variety of interstitial lung diseases (ILDs)
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Sunnybrook collaborates with Boehringer Ingelheim Canada to enhance care for complex cardiovascular patients
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Health Canada issues Notice of Compliance (NOC) for Jardiance® (empagliflozin) for the treatment of heart failure with reduced ejection fraction
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
Alberta Boehringer Ingelheim collaboration fund announces new research for patients living with respiratory disease
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease
EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
New health projects empower Indigenous communities to address chronic diseases
New health projects empower Indigenous communities to address chronic diseases
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
New empagliflozin data shows statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction